Quick Answer
Jazz Pharmaceuticals plc reported Total Assets of $11.66 billion for the year ending 2025.
- Jazz Pharmaceuticals plc showed a decrease of -2.9% in Total Assets from 2024 to 2025.
- This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $193.41 million | Q3 2011: $207.81 million | Q1 2012: $895.36 million | Q2 2012: $1.70 billion | Q3 2012: $1.73 billion | Q1 2013: $2.01 billion | Q2 2013: $2.09 billion | Q3 2013: $2.19 billion | Q1 2014: $3.20 billion | Q2 2014: $3.16 billion | Q3 2014: $3.35 billion | Q1 2015: $3.24 billion | Q2 2015: $3.39 billion | Q3 2015: $3.46 billion | Q1 2016: $3.53 billion | Q2 2016: $3.45 billion | Q3 2016: $4.93 billion | Q1 2017: $4.82 billion | Q2 2017: $4.80 billion | Q3 2017: $5.00 billion | Q1 2018: $5.29 billion | Q2 2018: $5.35 billion | Q3 2018: $5.49 billion | Q1 2019: $5.28 billion | Q2 2019: $5.49 billion | Q3 2019: $5.53 billion | Q1 2020: $5.22 billion | Q2 2020: $6.07 billion | Q3 2020: $6.29 billion | Q1 2021: $6.76 billion | Q2 2021: $13.21 billion | Q3 2021: $12.48 billion | Q1 2022: $11.77 billion | Q2 2022: $11.20 billion | Q3 2022: $10.38 billion | Q1 2023: $11.05 billion | Q2 2023: $11.26 billion | Q3 2023: $11.20 billion | Q1 2024: $11.33 billion | Q2 2024: $11.36 billion | Q3 2024: $12.26 billion | Q1 2025: $11.53 billion | Q2 2025: $10.94 billion | Q3 2025: $11.36 billion.
- Over the full 16 years of available data (2010 to 2025), Jazz Pharmaceuticals plc's Total Assets has grown by 8,490.2%.
- Historical annual values: Fiscal year 2025: $11.66 billion | Fiscal year 2024: $12.01 billion | Fiscal year 2023: $11.39 billion | Fiscal year 2022: $10.84 billion | Fiscal year 2021: $12.30 billion | Fiscal year 2020: $6.54 billion | Fiscal year 2019: $5.54 billion | Fiscal year 2018: $5.20 billion | Fiscal year 2017: $5.12 billion | Fiscal year 2016: $4.80 billion | Fiscal year 2015: $3.33 billion | Fiscal year 2014: $3.34 billion | Fiscal year 2013: $2.24 billion | Fiscal year 2012: $1.97 billion | Fiscal year 2011: $253.57 million | Fiscal year 2010: $135.73 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: